Wells Fargo Sets $9 PT for MannKind Corporation (MNKD)

MannKind Corporation (NASDAQ:MNKD) is highlighted as one of the 13 Best Healthcare Stocks to Buy Under $10, with Wells Fargo analyst Tiago Fauth maintaining a Buy rating and setting a price target of $9.00 on May 8. The company’s growth potential and strategic advancements, particularly in the MNKD-101 program, contribute to Fauth’s positive outlook. MannKind Corporation focuses on developing innovative therapeutic devices and products for endocrine and orphan lung diseases, with a pipeline that includes Afrezza, V-Go, and other products. While MNKD shows promise as an investment, some believe that certain AI stocks offer greater upside potential with less downside risk. For more information on potential investment opportunities, consider exploring other stocks that show strong growth potential.

Read more at Yahoo Finance: Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT